Former Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs, Andrew C. Weber Expert on Chemical and Biological Weapons, Dr. Gregory Koblentz has joined Advisory Board.
Former Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs, Andrew C. Weber
Expert on Chemical and Biological Weapons, Dr. Gregory Koblentz
DURHAM, N.C., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Heat Biologics (“Heat”)(NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announces the following additions to its newly formed Biothreat Advisory Board: Andrew C. Weber, Former Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs; and Dr. Gregory Koblentz, Associate Professor at George Mason University and leading expert on chemical and biological weapons. These individuals join David Lasseter, Former Deputy Assistant Secretary of Defense for Countering Weapons of Mass Destruction, and Former US Representative Jack Kingston, who also serves as the Secretariat of the Alliance for Biosecurity.
Jeff Wolf, Chief Executive Officer of Heat, commented, “We are delighted to announce the addition of these highly renowned individuals in the fields of biosecurity and biodefense to our biothreat advisory board. As the former Assistant Secretary of Defense for Nuclear, Chemical and Biological Defense Programs, Mr. Weber has deep insight into the potential threats facing our nation and best potential avenues for developing effective solutions. Professor Koblentz is one of the leading global thought leaders in the field of chemical and biological weapons.”
Andy Weber is a Senior Fellow at the Council on Strategic Risks’ Janne E. Nolan Center on Strategic Weapons. He is also a member of the Council on Foreign Relations. Mr. Weber has dedicated his professional life to countering nuclear, chemical, and biological threats and to strengthening global health security. Mr. Weber’s decades of U.S. government service included five-and-a-half years as the Assistant Secretary of Defense for Nuclear, Chemical and Biological Defense Programs. He was a driving force behind reducing biological weapons threats, and destroying Libyan and Syrian chemical weapons stockpiles. In addition, he coordinated U.S. leadership of the international Ebola response for the Department of State.
Dr. Gregory D. Koblentz is an Associate Professor and Director of the Biodefense Graduate Program at George Mason University’s Schar School of Policy and Government. He is also an Associate Faculty at the Center for Security Policy Studies at George Mason and a member of the Scientists Working Group on Chemical and Biological Security at the Center for Arms Control and Non-Proliferation in Washington, DC. He has published widely on issues related to the proliferation of nuclear, biological, and chemical weapons and has briefed the UN Security Council on the threat of non-state actors acquiring and using weapons of mass destruction.
“We are very enthusiastic about our efforts in the biodefense space,” added Wolf. “Our Biothreat Advisory Board brings deep insight and relationships that we expect will be instrumental in advancing our new biothreat initiatives. We look forward to providing more details as developments unfold.”
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, various infectious disease/biological threat programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
For more information, please visit: www.heatbio.com, and also follow us on Twitter.
Forward Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements regarding thecontributions to be made by the advisory board, theBoard bringing deep insight and relationships that will be instrumental in advancing our new biothreat initiativesand providing more details as developments unfold. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of Heat to successfully develop a new biosecurity/biodefense initiative and benefit from the contributions of the advisory board, the ability of Heat’s therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat’s ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat’s ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities and its cash and short-term investments providing significant runway to fund Heat’s current clinical programs and further expand Heat’s therapeutic portfolio , its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat’s annual report on Form 10-K for the year ended December 31, 2020 filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
investorrelations@heatbio.com
